| | |
Whole study group
|
Fibromyalgia classification
|
|---|
| | |
Median (IQR) or %
|
Yes
|
No
|
|---|
|
N
| |
50
|
24
|
26
|
|
Female
| |
76%
|
75%
|
77%
|
|
Age
| |
60 (54–69)
|
58 (54–66)
|
63 (54–70)
|
|
Current smoker
| |
21%
|
26%
|
17%
|
|
Analgesia
|
Any
|
69%
|
71%
|
65%
|
| |
Paracetamol
|
63%
|
71%
|
54%
|
| |
NSAID
|
16%
|
17%
|
15%
|
| |
Opiate
|
37%
|
38%
|
35%
|
|
DMARD
|
Methotrexate
|
59%
|
50%
|
65%
|
| |
Sulfasalazine
|
22%
|
15%
|
25%
|
| |
Other nonbiologic DMARD
|
36%
|
40%
|
30%
|
| |
Combination nonbiologic DMARD
|
24%
|
29%
|
15%
|
|
Biologic therapy
| |
12%
|
8%
|
16%
|
|
Combination therapy
|
31%
|
33%
|
27%
|
|
Glucocorticosteroid
| |
20%
|
15%
|
21%
|
|
Pressure pain threshold
| | | |
| |
Knee
|
173 (119–287)
|
133 (58–181)**
|
239 (169–470)
|
| |
Tibia
|
140 (98–246)
|
108 (61–167)**
|
187 (122–337)
|
| |
Sternum
|
155 (85–211)
|
111 (70–175)**
|
179 (149–256)
|
- Demographics of the entire study group and a comparison between participants that did or did not satisfy fibromyalgia-classification criteria. Other nonbiologic DMARDs were azathioprine (n = 2), leflunomide (n = 4), gold (n = 3), hydroxychloroquine (n = 6), and cyclosporin (n = 3). Biologic therapies were antitumor-necrosis factor agents (n=4), rituximab (n=1), or abatacept (n=1). Combination DMARDs; two or more biologic or nonbiologic DMARDs. **P < 0.01 (compared with participants who did not satisfy criteria for fibromyalgia).
